179 filings
8-K
OCUP
Ocuphire Pharma Inc
17 Apr 24
Departure of Directors or Certain Officers
4:23pm
8-K
OCUP
Ocuphire Pharma Inc
27 Mar 24
Regulation FD Disclosure
4:26pm
8-K
OCUP
Ocuphire Pharma Inc
8 Mar 24
Ocuphire Pharma Announces Financial Results for Fourth Quarter and Full Year 2023 and Provides Corporate Update
8:21am
8-K
OCUP
Ocuphire Pharma Inc
16 Feb 24
Ocuphire Pharma Strengthens Leadership Team with Key Appointments
4:03pm
8-K
OCUP
Ocuphire Pharma Inc
5 Dec 23
Departure of Directors or Certain Officers
7:15pm
8-K
uus302i c6d15n3
27 Nov 23
Ocuphire Pharma Announces Appointment of Joseph Schachle, M.B.A., as Chief Operating Officer
8:45am
8-K
008ju
13 Nov 23
Ocuphire Pharma Announces Financial Results for Third Quarter 2023 and Provides Corporate Update
8:12am
8-K
gmprf65ustjvjk
2 Nov 23
Ocuphire Corporate Presentation November 2023
8:44am
8-K
mhlraw3wac lzmv
1 Nov 23
Ocuphire Pharma Announces Appointment of George Magrath, M.D., M.B.A., M.S., as Chief Executive Officer and Director
4:21pm
8-K
1nz8abq560 prv
27 Sep 23
RYZUMVI Expected to be Commercially Available in the U.S. in the First Half of 2024
8:45am
8-K
imc09k 9ekflsy8
11 Aug 23
Ocuphire Pharma Announces Financial Results for Second Quarter 2023 and Provides Corporate Update
9:27am
8-K
eqr yfqt7falgum2e
1 Aug 23
Restore Vision & Clarity Ocuphire Corporate Presentation August 2023
11:21am
8-K
lq2xd7 hm
14 Jun 23
Departure of Directors or Certain Officers
4:31pm
8-K
zx6w1haaa13l6v9l9s
8 Jun 23
Submission of Matters to a Vote of Security Holders
5:58pm
8-K
3xf2nc5idk
2 Jun 23
Amendments to Articles of Incorporation or Bylaws
4:30pm
8-K
insba agw5r2pn
15 May 23
Ocuphire Pharma Announces Financial Results for First Quarter 2023 and Provides Corporate Update
8:07am
8-K
0f4twk rxism
21 Apr 23
Ocuphire Appoints Rick Rodgers as Interim Chief Executive Officer
8:10am
8-K
ncjifme6mhthuhv yj0
30 Mar 23
Ocuphire Pharma Announces Financial Results for Fourth Quarter and Year Ended 2022 and Provides Corporate Update
9:05am
8-K
gx7xvonhzh2ps 1d
25 Jan 23
Regulation FD Disclosure
4:15pm
8-K
ngzxfzvlk nm
6 Dec 22
Ocuphire Pharma Announces Submission of New Drug Application to FDA for Nyxol® Eye Drops for Reversal of Mydriasis
6:37am